Stock ZEAL ZEALAND PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen
Other stock markets
 10:59:36 2024-04-26 am EDT 		5-day change 1st Jan Change
622 DKK +3.84% Intraday chart for Zealand Pharma A/S +6.60% +66.67%
Apr. 04 U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year DJ
Mar. 20 Zealand Pharma A/S Approves Appointments to the Board CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 8,472 8,766 6,271 10,366 21,785 38,735 - -
Enterprise Value (EV) 1 7,092 7,638 5,364 9,712 20,152 36,122 36,049 35,583
P/E ratio -13.9 x -10 x -6.11 x -7.74 x -30 x -101 x -717 x -137 x
Yield - - - - - - - -
Capitalization / Revenue 205 x 24.8 x 21.4 x 99.7 x 63.6 x 55.8 x 34 x 26.4 x
EV / Revenue 172 x 21.6 x 18.3 x 93.4 x 58.8 x 52 x 31.6 x 24.2 x
EV / EBITDA -12.3 x -10.2 x -5.3 x -13.5 x -36.8 x -151 x -1,241 x -517 x
EV / FCF -16.5 x -10.7 x -4.35 x -10.2 x -46.1 x -132 x 87.4 x 140 x
FCF Yield -6.07% -9.34% -23% -9.82% -2.17% -0.76% 1.14% 0.71%
Price to Book 6.82 x 6.89 x 6.83 x 11.4 x 13.7 x 12.9 x 12.2 x 11.6 x
Nbr of stocks (in thousands) 35,990 39,735 43,216 51,470 58,374 62,275 - -
Reference price 2 235.4 220.6 145.1 201.4 373.2 622.0 622.0 622.0
Announcement Date 3/11/20 3/11/21 3/10/22 3/1/23 2/27/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 41.3 353.3 292.6 104 342.8 694 1,140 1,470
EBITDA 1 -574.3 -749.7 -1,012 -719.2 -547.2 -239.8 -29.05 -68.84
EBIT 1 -587.9 -792.4 -1,052 -837.2 -572.2 -451.2 -143.3 163.3
Operating Margin -1,423.49% -224.27% -359.7% -805.06% -166.94% -65.02% -12.57% 11.11%
Earnings before Tax (EBT) 1 -576.7 -839.7 -1,027 -972 -708.9 -292.1 106.7 536.9
Net income 1 -571.5 -846.7 -1,018 -1,202 -703.7 -383.1 -272.2 -321.8
Net margin -1,383.88% -239.65% -348.01% -1,156.05% -205.3% -55.2% -23.88% -21.89%
EPS 2 -16.91 -22.07 -23.75 -26.02 -12.44 -6.138 -0.8673 -4.529
Free Cash Flow 1 -430.5 -713.8 -1,234 -953.9 -436.9 -273.2 412.7 253.7
FCF margin -1,042.35% -202.02% -421.82% -917.35% -127.46% -39.36% 36.2% 17.26%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/11/20 3/11/21 3/10/22 3/1/23 2/27/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 106.4 54.02 50.79 50.21 43.71 23.92 13.63 10.41 295.5 23.24 3.339 9.104 47.88 198.7 -
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -211.8 -289.7 -343.4 -293.3 -162.1 -241 -168.7 -195.4 45.28 -253.5 -192.6 -195.6 -168.1 -325.7 -324.6
Operating Margin -199.05% -536.42% -676.17% -584.12% -370.76% -1,007.18% -1,237.69% -1,877.25% 15.32% -1,090.94% -5,769.2% -2,148.12% -350.97% -163.88% -
Earnings before Tax (EBT) 1 -195.7 -285.8 -210.4 -488.5 -153.7 -322.4 -195.3 -321 72.83 -265.3 -252.8 -262.8 -272.7 -307.2 -
Net income 1 -198.9 -280.3 -222.8 -488.5 -148.3 -342.4 -193.6 -319.5 74.14 -264.8 -177.6 -186.2 -195.1 -372.9 -337.1
Net margin -186.91% -518.86% -438.79% -972.97% -339.35% -1,431.34% -1,420.84% -3,070.07% 25.09% -1,139.44% -5,318.96% -2,045.2% -407.44% -187.61% -
EPS 2 -4.610 -6.490 -5.160 -11.04 -3.210 -6.740 -3.760 -5.500 1.230 -4.600 -4.360 -4.465 -4.690 -5.075 -5.340
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/11/21 3/10/22 5/12/22 8/11/22 11/10/22 3/1/23 5/11/23 8/17/23 11/9/23 2/27/24 - - - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 1,381 1,127 907 654 1,633 2,613 2,686 3,152
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -430 -714 -1,234 -954 -437 -273 413 254
ROE (net income / shareholders' equity) -48.5% -68.5% -94.4% -138% -58.4% 24.8% -4.31% 30.7%
ROA (Net income/ Total Assets) -40.4% -50.4% -53.2% - - 21% 1.99% 29%
Assets 1 1,415 1,681 1,915 - - -1,822 -13,671 -1,108
Book Value Per Share 2 34.50 32.00 21.30 17.70 27.30 48.10 51.00 53.60
Cash Flow per Share 2 -12.10 -17.90 -28.30 -20.40 -7.520 -10.40 9.130 -4.730
Capex 1 21 25 22.1 11.7 11.2 9.32 10.9 13.6
Capex / Sales 50.93% 7.09% 7.57% 11.26% 3.28% 1.34% 0.96% 0.92%
Announcement Date 3/11/20 3/11/21 3/10/22 3/1/23 2/27/24 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Zealand Pharma A/S

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
622 DKK
Average target price
782 DKK
Spread / Average Target
+25.72%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ZEALAND PHARMA A/S Stock Zealand Pharma A/S
+66.67% 5.55B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ZEAL Stock
  4. Financials Zealand Pharma A/S